Supreme Court preserves access to widely used abortion pill, while lawsuit plays out

The Supreme Court has issued an order preserving access to mifepristone, a widely used abortion pill, while a legal challenge continues. This decision rejects lower-court restrictions that would have required in-person doctor visits and halted mail delivery of the medication. The ruling ensures that access to the drug remains unchanged, likely until at least next year, as the case proceeds through the judicial system. The emergency request was granted to the drug's manufacturers, who were appealing an appellate court ruling against current FDA guidelines. Justices Clarence Thomas and Samuel Alito dissented, arguing that the companies were profiting from a potentially illegal enterprise. The underlying lawsuit, filed by Louisiana, seeks to challenge the FDA's authority and safety determinations regarding the pill's distribution. Despite the ongoing legal tension, the Supreme Court's action maintains the status quo, which has been in place since the FDA removed in-person requirements five years ago. Medication abortions currently account for nearly two-thirds of all abortions in the United States. While abortion-rights advocates expressed relief at the court's decision, they emphasized that the long-term future of access remains uncertain. Meanwhile, anti-abortion groups continue to push for tighter restrictions, signaling that the debate over the drug's availability is far from resolved.